Clinical trial · Interventional
The Feasible Research of Infrared Endoscope to Diagnose Early Gastric Cancer
The Feasible Research of Infrared Endoscope to Diagnose Early Gastric Cancer and Evaluate the Invasive Depth of Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The gastric cancer is the second most frequently diagnosed cancer and the third leading cause of cancer death in China.80%-90% patients were detected at middle and later stage.The five-year survival rate for advanced gastric cancer patients is less than 10% due to the shortage of effective treatment method.The five-year survival rate for early gastric cancer patients is beyond 90%.The reason for poor diagnosis and treatment is that current methods do not achieve the diagnosis of early gastric cancer.Endoscopy with biopsy is still the main method for confirming gastric cancer.But it is limited to identify early gastric cancer and it leads to the low diagnostic rate of early gastric cancer. Infrared endoscopic imaging is a new great potential method of diagnosis of early gastric cancer, since the first report in the 1990s, people have been exploring in this field. Through intravenous injection of exogenous contrast medium, such as the indocyanine green, it makes mucosal lesions highlight,and avoids the interference of background light.If specific target molecular is linked to the contrast medium,the specific imaging of the lesion can be presented. What is more,due to the strong penetration power of infrared light,its imaging depth also increases significantly.Indocyanine green had also been demonstrated safe in clinical studies and widely used. On this basis,we apply for the research about near-infrared endoscopy to diagnose early gastric cancer,and discuss its feasibility of the infrared endoscopy to diagnose early gastric cancer and clinical value.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early Gastric Cancer | Early Gastric Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| infrared endoscopy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cancer group
- description
- All patients receive the infrared endoscopy after injecting indocyanine green(ICG) intravenously.
- interventionNames
- Device: infrared endoscopy
- type
- OTHER
- label
- Non-cancer group
- description
- All patients receive the infrared endoscopy after injecting ICG intravenously.
- interventionNames
- Device: infrared endoscopy
Primary outcomes (1)
- measure
- the lesion of early gastric cancer by infrared endoscopy
- timeFrame
- up to two years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age:18-70 2. Sex:unlimited; 3. Group 1:patients with EGC,willing to receive treatment under endoscopy(EMR/ESD) 4. Group 2:patients for screening,or have some general symptoms dyspepsia、epigastric pain)who need to be examined by endoscopy 5. Informed consent issued Exclusion Criteria: 1. Severe liver and kidney disease; 2. Iodine, seafood or other severe allergies history; 3. Patients with severe heart or pulmonary disease which is not suitable for endoscopic examination 4. Higher blood risk of esophageal varices 5. Pregnant or lactating female 6. Without patient's consent 7. The investigator considers other condition which is not suitable for participation
References
Publications (0)
Data not yet available